Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

CSE Bulletin: INDEX - CSE 25 INDEX QUARTERLY REBALANCING

C.PBIT, C.MMAX, C.DTC, CMND

Toronto, Ontario--(Newsfile Corp. - Le 16 mars/March 2023) - The quarterly rebalancing of the CSE 25 Index will result in the following changes, effective after the close on Friday, March 17, 2023.

Le rééquilibrage trimestriel de l’indice composé du CSE 25 entraînera les modifications suivantes, en vigueur à la fermeture le vendredi 17 mars 2023.

ADDITIONS

Symbol Issuer Sector
DTC Defence Therapeutics Inc Life Sciences
PBIT POSaBIT Systems Corporation Technology

DELETIONS

Symbol Issuer Sector
CMND Clearmind Medicine Inc. Life Sciences
MMAX Metamaterial Exchangeco Inc Technology

Deletions from CSE 25 do not necessarily mean a deletion from the Composite.

Les suppressions de CSE 25 ne signifient pas nécessairement une suppression du composite.


For more information about the CSE 25 Index, including the full list of securities and the index methodology, visit the CSE website.

Pour plus d’information sur l’indice composé du CSE 25, incluant la liste complète des titres et la méthodologie indicielle, rendez-vous sur le site Web du CSE.

Contact Information/Coordonnées

Index Management/Gestion de l’indice :
Robert Cook
Senior Vice-President Market Development/Vice-président principal du développement
Robert.Cook@thecse.com (416) 367-7349

Media Relations/Relations avec la presse:
Richard Carleton, CEO
Richard.Carleton@thecse.com (416) 367-7360